BION Stock Analysis: BB Biotech | SW
Biotechnology | SW, Switzerland | Market Cap: 2.928m CHF | 12M Return: 81% | CH0038389992 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.82M
Rev. Trend: 84.5%
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BB Biotech AG (BION) is a publicly listed investment company domiciled in Switzerland, managed by Bellevue Asset Management AG. Formed in 1993, the fund invests in global public equity markets with a concentrated focus on companies operating in medications and diagnostics based on modern biotechnology. Portfolio construction relies on fundamental analysis, and the company is classified within the Health Care sector under the GICS Biotechnology sub-industry, with a mid-cap market capitalization.
The companys business model is that of a closed-end fund, which allows it to hold a concentrated portfolio of biotechnology equities and trade its own shares on a stock exchange at prices that may diverge from its net asset value. Its investment universe spans the full biotechnology value chain, from clinical-stage developers to commercial-stage drug and diagnostics manufacturers.
- FDA approval decisions for portfolio company drug candidates
- Large pharma M&A wave lifts biotech sector valuations
- US dollar weakness pressures Swiss franc-reported NAV
| Net Income: 1.35b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -13.82 > 1.0 |
| NWC/Revenue: 2.12k% < 20% (prev 1.65k%; Δ 465.6% < -1%) |
| CFO/TA 0.10 > 3% & CFO 302.8m > Net Income 1.35b |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (55.1m) vs 12m ago 0.68% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 5.92% > 50% (prev 6.05%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: 3.05k > 6 (EBIT TTM 1.35b / Interest Expense TTM 443k) |
| A: 1.00 (Total Current Assets 3.09b - Total Current Liabilities 0.0) / Total Assets 3.09b |
| B: 0.99 (Retained Earnings 3.07b / Total Assets 3.09b) |
| C: 0.55 (EBIT TTM 1.35b / Avg Total Assets 2.47b) |
| D: 583.0 (Book Value of Equity 3.08b / Total Liabilities 5.29m) |
| Altman-Z'' = 625.6 = AAA |
As of August 22, 2026, the stock is trading at CHF 55.90 with a total of 54,814 shares traded. Over the past week, the price has changed by +5.27%, over one month by +11.35%, over three months by +26.90% and over the past year by +80.97%.
Current recommended Stop Loss: 54.30 (which is 2.9% or 1.4 ATR below the current price).
BB Biotech has no consensus analysts rating.
P/E Trailing = 2.1612
P/E Forward = 11.8203
P/S = 2.7635
P/B = 0.9512
Revenue TTM = 146.0m CHF
EBIT TTM = 1.35b CHF
EBITDA TTM = 1.35b CHF
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.93b CHF (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 3.05k (Ebit TTM 1.35b / Interest Expense TTM 443k)
EV/FCF = 9.67x (Enterprise Value 2.93b / FCF TTM 302.8m)
FCF Yield = 10.34% (FCF TTM 302.8m / Enterprise Value 2.93b)
FCF Margin = 207.4% (FCF TTM 302.8m / Revenue TTM 146.0m)
Net Margin = 924.0% (Net Income TTM 1.35b / Revenue TTM 146.0m)
Gross Margin = unknown ((Revenue TTM 146.0m - Cost of Revenue TTM 55.0k) / Revenue TTM)
Tobins Q-Ratio = 0.95 (Enterprise Value 2.93b / Total Assets 3.09b)
Interest Expense / Debt = unknown (Interest Expense 443k / Debt none)
Taxrate = 0.01% (71.0k / 1.35b)
NOPAT = 1.35b (EBIT 1.35b * (1 - 0.01%))
Current Ratio = unknown (Total Current Assets 3.09b / Total Current Liabilities 0.0)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 1.35b)
Debt / FCF = unknown (Net Debt none / FCF TTM 302.8m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 54.68% (Net Income 1.35b / Total Assets 3.09b)
RoE = 49.95% (Net Income TTM 1.35b / Total Stockholder Equity 2.70b)
RoCE = 43.71% (EBIT 1.35b / Capital Employed (Total Assets 3.09b - Current Liab 0.0))
RoIC = 9.98k% (out of range, set to none) (EBIT 1.35b / (Assets 3.09b - Curr.Liab 0.0 - Cash 3.08b))
WACC = 7.13% (E(2.93b)/V(2.93b) * Re(7.13%) + (debt-free company))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.38 | Cagr: 0.25%
[DCF] Terminal Value 73.10% ; FCFF base≈356.0m ; Y1≈312.2m ; Y5≈252.2m
[DCF] Fair Price = 73.41 (EV 4.05b - Net Debt 0.0 = Equity 4.05b / Shares 55.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 84.48 | Revenue CAGR: 4.58k% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-0.61 | Chg30d=-112.36% | Revisions=+25% | GrowthEPS=-105.8% | GrowthRev=+108.3%
EPS next Year (2027-12-31): EPS=-0.66 | Chg30d=-111.79% | Revisions=+0% | GrowthEPS=-8.4% | GrowthRev=+0.0%